Drug Trial Radar · NCT03973151
Study of HL-085 in NRAS Mutant Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Sep 1, 2017
Primary completion
Jan 18, 2021
Study completion Jan 18, 2021
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .
Conditions
- Melanoma
Interventions
HL-085Drug
HL-085 is one MEK inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: Duration of the study, estimated to be approximately 24 months.
- Maximum tolerated dose (MTD)Time frame: DLTs within the first cycle of therapy (up to 35 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.